Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Navicon acquired Product Portfolio from Takeda Pharmaceutical Company Limited.

09/23/2021 EDT

Navicon acquired Product Portfolio from Takeda Pharmaceutical Company Limited (TSE:4502) on late 2019. Navicon completed the acquisition of Product Portfolio from Takeda Pharmaceutical Company Limited (TSE:4502) on late 2019.


ę S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
02:43pPhathom Pharmaceuticals Stock Slumps Following Stock Offering Announcement
MT
10:48aTakeda Pharmaceutical to Buy GammeDelta Therapeutics
MT
09:28aTakeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic Cell ..
PU
09:17aTakeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic &gamm..
BU
10/26Phathom Pharmaceuticals Launches 5 Million Share Offering
MT
10/21TAKEDA PHARMACEUTICAL : to Hold Second Quarter FY2021 Earnings Conference Calls
PU
10/20NOVAVAX : Dismisses Media Report on COVID-19 Vaccine Quality, Production Delays; Shares Do..
MT
10/20NOVAVAX : Refutes Media Report on its COVID-19 Vaccine Quality, Production Delays
MT
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18Wave Life Sciences Ltd. Announces an Amendment to its Ongoing Collaboration with Takeda..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 398 B 29 855 M 29 855 M
Net income 2022 249 B 2 185 M 2 185 M
Net Debt 2022 3 258 B 28 621 M 28 621 M
P/E ratio 2022 20,4x
Yield 2022 5,64%
Capitalization 5 018 B 44 093 M 44 088 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 191,00 JPY
Average target price 4 372,86 JPY
Spread / Average Target 37,0%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.02%43 832
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231